Title : Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.

Pub. Date : 2002 Apr 26

PMID : 12054639






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. alvocidib cyclin dependent kinase 1 Homo sapiens
2 Flavopiridol has been shown to potently inhibit CDK1 and 2 (cyclin-dependent kinases 1 and 2) and most recently it has been found that it also inhibits CDK9. alvocidib cyclin dependent kinase 1 Homo sapiens
3 This structural model indicates that the inhibitor strongly binds to the ATP-binding pocket of CDK9 and the structural comparison of the complex CDK2-flavopiridol correlates the structural differences with differences in inhibition of these CDKs by flavopiridol. alvocidib cyclin dependent kinase 1 Homo sapiens
4 This structural model indicates that the inhibitor strongly binds to the ATP-binding pocket of CDK9 and the structural comparison of the complex CDK2-flavopiridol correlates the structural differences with differences in inhibition of these CDKs by flavopiridol. alvocidib cyclin dependent kinase 1 Homo sapiens